Prothena Corporation plc
US ˙ NasdaqGS ˙ IE00B91XRN20

Introduction

This page provides a comprehensive analysis of the known insider trading history of William P Scully. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate William P Scully has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:PRTA / Prothena Corporation plc 10% Owner 47,000
US:MBLX / Metabolix, Inc. 10% Owner 2,933,333
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by William P Scully. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases PRTA / Prothena Corporation plc - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in PRTA / Prothena Corporation plc. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2025-01-14 PRTA SCULLY WILLIAM P 100,000 12.7904 100,000 12.7904 1,279,040 13 16.0400 324,960 25.41
2024-12-31 PRTA SCULLY WILLIAM P 1,200 13.3652 1,200 13.3652 16,038
2024-12-31 PRTA SCULLY WILLIAM P 800 13.3940 800 13.3940 10,715
2024-12-31 PRTA SCULLY WILLIAM P 30,000 12.9880 30,000 12.9880 389,640
2024-12-20 PRTA SCULLY WILLIAM P 2,000 15.9065 2,000 15.9065 31,813
2024-12-18 PRTA SCULLY WILLIAM P 73,436 13.9260 73,436 13.9260 1,022,670

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

PRTA / Prothena Corporation plc Insider Trades
Insider Sales PRTA / Prothena Corporation plc - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in PRTA / Prothena Corporation plc. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

PRTA / Prothena Corporation plc Insider Trades
Insider Purchases YTENQ / Yield10 Bioscience, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in PRTA / Prothena Corporation plc. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2015-09-17 MBLX SCULLY WILLIAM P 31,833 2.1051 31,833 2.1051 67,012 731
2015-09-15 MBLX SCULLY WILLIAM P 47,500 2.1529 47,500 2.1529 102,263
2015-09-15 MBLX SCULLY WILLIAM P 47,150 2.1529 47,150 2.1529 101,509
2015-09-14 MBLX SCULLY WILLIAM P 20,000 2.1782 20,000 2.1782 43,564
2015-09-10 MBLX SCULLY WILLIAM P 25,000 2.7059 25,000 2.7059 67,648
2015-09-10 MBLX SCULLY WILLIAM P 25,000 2.2059 25,000 2.2059 55,148
2015-09-08 MBLX SCULLY WILLIAM P 40,000 2.2267 40,000 2.2267 89,068
2015-09-04 MBLX SCULLY WILLIAM P 7,750 2.0521 7,750 2.0521 15,904
2015-09-03 MBLX SCULLY WILLIAM P 35,000 2.1685 35,000 2.1685 75,898
2015-08-28 MBLX SCULLY WILLIAM P 26,600 1.9944 26,600 1.9944 53,051

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

YTENQ / Yield10 Bioscience, Inc. Insider Trades
Insider Sales YTENQ / Yield10 Bioscience, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in PRTA / Prothena Corporation plc. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2016-09-13 MBLX SCULLY WILLIAM P 23,333 0.3314 23,333 0.3314 7,733 730
2016-09-12 MBLX SCULLY WILLIAM P 45,000 0.3287 45,000 0.3287 14,792
2016-09-09 MBLX SCULLY WILLIAM P 65,000 0.3367 65,000 0.3367 21,886
2016-09-08 MBLX SCULLY WILLIAM P 100,000 0.3555 100,000 0.3555 35,550

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

YTENQ / Yield10 Bioscience, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by William P Scully as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2025-05-02 2025-01-15 4 PRTA PROTHENA CORP PUBLIC LTD CO
Ordinary Shares, par value $0.01 per share
G - Gift -12,000 47,000 -20.34
2025-05-02 2025-01-14 4 PRTA PROTHENA CORP PUBLIC LTD CO
Ordinary Shares, par value $0.01 per share
P - Purchase 100,000 735,993 15.72 12.79 1,279,040 9,413,645
2025-05-02 2025-01-03 4 PRTA PROTHENA CORP PUBLIC LTD CO
Ordinary Shares, par value $0.01 per share
G - Gift -1,000 635,993 -0.16
2025-05-02 2025-01-02 4 PRTA PROTHENA CORP PUBLIC LTD CO
Ordinary Shares, par value $0.01 per share
G - Gift -13,200 636,993 -2.03
2025-05-02 2024-12-31 4 PRTA PROTHENA CORP PUBLIC LTD CO
Ordinary Shares, par value $0.01 per share
P - Purchase 30,000 650,193 4.84 12.99 389,640 8,444,707
2025-05-02 2024-12-31 4 PRTA PROTHENA CORP PUBLIC LTD CO
Ordinary Shares, par value $0.01 per share
P - Purchase 800 620,193 0.13 13.39 10,715 8,306,865
2025-05-02 2024-12-31 4 PRTA PROTHENA CORP PUBLIC LTD CO
Ordinary Shares, par value $0.01 per share
P - Purchase 1,200 619,393 0.19 13.37 16,038 8,278,311
2025-05-02 2024-12-20 4 PRTA PROTHENA CORP PUBLIC LTD CO
Ordinary Shares, par value $0.01 per share
G - Gift -40,000 59,000 -40.40
2025-05-02 2024-12-20 4 PRTA PROTHENA CORP PUBLIC LTD CO
Ordinary Shares, par value $0.01 per share
G - Gift -500 618,193 -0.08
2025-05-02 2024-12-20 4 PRTA PROTHENA CORP PUBLIC LTD CO
Ordinary Shares, par value $0.01 per share
P - Purchase 2,000 618,693 0.32 15.91 31,813 9,841,240
2025-05-02 2024-12-19 4 PRTA PROTHENA CORP PUBLIC LTD CO
Ordinary Shares, par value $0.01 per share
G - Gift -681,000 616,693 -52.48
2025-05-02 2024-12-18 4 PRTA PROTHENA CORP PUBLIC LTD CO
Ordinary Shares, par value $0.01 per share
P - Purchase 73,436 1,297,693 6.00 13.93 1,022,670 18,071,673
2025-05-02 2024-12-18 4 PRTA PROTHENA CORP PUBLIC LTD CO
Ordinary Shares, par value $0.01 per share
G - Gift 430,000 1,224,257 54.14
2025-05-01 3 PRTA PROTHENA CORP PUBLIC LTD CO
Ordinary Shares, par value $0.01 per share
794,257
2025-05-01 3 PRTA PROTHENA CORP PUBLIC LTD CO
Ordinary Shares, par value $0.01 per share
75,950
2025-05-01 3 PRTA PROTHENA CORP PUBLIC LTD CO
Ordinary Shares, par value $0.01 per share
68,000
2025-05-01 3 PRTA PROTHENA CORP PUBLIC LTD CO
Ordinary Shares, par value $0.01 per share
99,000
2016-09-14 2016-09-13 4 MBLX METABOLIX, INC.
Common
S - Sale -23,333 2,933,333 -0.79 0.33 -7,733 972,107
2016-09-14 2016-09-12 4 MBLX METABOLIX, INC.
Common
S - Sale -45,000 2,956,666 -1.50 0.33 -14,792 971,856
2016-09-12 2016-09-09 4 MBLX METABOLIX, INC.
Common
S - Sale -65,000 3,001,666 -2.12 0.34 -21,886 1,010,661
2016-09-12 2016-09-08 4 MBLX METABOLIX, INC.
Common
S - Sale -100,000 3,066,666 -3.16 0.36 -35,550 1,090,200
2016-01-07 2015-09-10 4/A MBLX METABOLIX, INC.
Common Stock
P - Purchase 25,000 3,067,683 0.82 2.21 55,148 6,767,002
2016-01-07 2015-09-15 4/A MBLX METABOLIX, INC.
Common Stock
P - Purchase 47,150 3,134,833 1.53 2.15 101,509 6,748,982
2015-09-21 2015-09-17 4 MBLX METABOLIX, INC.
Common
P - Purchase 31,833 3,167,016 1.02 2.11 67,012 6,666,885
2015-09-16 2015-09-15 4 MBLX METABOLIX, INC.
Common Stock
P - Purchase 47,500 3,135,183 1.54 2.15 102,263 6,749,735
2015-09-16 2015-09-14 4 MBLX METABOLIX, INC.
Common Stock
P - Purchase 20,000 3,087,683 0.65 2.18 43,564 6,725,591
2015-09-14 2015-09-10 4 MBLX METABOLIX, INC.
Common Stock
P - Purchase 25,000 3,067,683 0.82 2.71 67,648 8,300,843
2015-09-10 2015-09-08 4 MBLX METABOLIX, INC.
Common Stock
P - Purchase 40,000 3,042,683 1.33 2.23 89,068 6,775,142
2015-09-08 2015-09-04 4 MBLX METABOLIX, INC.
Common Stock
P - Purchase 7,750 3,002,683 0.26 2.05 15,904 6,161,806
2015-09-08 2015-09-03 4 MBLX METABOLIX, INC.
Common Stock
P - Purchase 35,000 2,994,933 1.18 2.17 75,898 6,494,512
2015-09-01 2015-08-28 4 MBLX METABOLIX, INC.
Common Stock
P - Purchase 26,600 2,959,933 0.91 1.99 53,051 5,903,290
2014-11-03 2014-10-30 4 MBLX METABOLIX, INC.
Series B Convertible Preferred Stock
C - Conversion -8,000 0 -100.00
2014-11-03 2014-10-30 4 MBLX METABOLIX, INC.
Common Stock
C - Conversion 8,000,000 17,600,000 83.33
2014-08-29 3 MBLX METABOLIX, INC.
Common Stock
11,200,000
2014-08-29 3 MBLX METABOLIX, INC.
Common Stock
17,600,000
2014-08-29 3 MBLX METABOLIX, INC.
Common Stock
11,200,000
2014-08-29 3 MBLX METABOLIX, INC.
Common Stock
17,600,000
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)